TrialPloS one2018

Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study.

Oscar Fernández et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.